Namie KHADIJA UZMA FARUKI se Collected 29/12/2014 2:56:00PM Received 29/izy2014 3:01:17PM Lab No. 211717968, Age: 337 Wier: Female Reported Casa aaa Ae Status P Ret By: Or DEVENDRA SINGH Report Status Final Test Name Results Units Bio. Ref. Interval CA.125; OVARIAN CANCER MARKER, SERUM @ 9.00 Wit <35.00 s (GMA) Note 4. This testis not recommended to screen Ovarian cancer in the general population 2. False negative / positive results ere observed in patients receiving mouse monoclonal, antinogies. for diagnosis or therapy, 3. Patients with confirmed Ovarian cancer may show normal pre-treatment CA 125 levels. Hence this assay, regardiess of level, should nol be interpreted as absolute evidence for the presence or absence of malignant disease. The assay value should be used in conjunction with findings. from Clinical evaluation and other disgnostic procedures, Clinical Use = An aid in the management of ‘Ovarian cancer patients. Preoperative CA 128 level of < 65 U mt is ‘associated with a significantly greater 5 year survival rat. “ = Manitor the course of disease in patients with invasive epithelial ovarian cancer = Detection of residual tumor in patients with Primary epithelial ovarian cancer who: have undergone first line therapy. Persistent elevation of CA 125 levels after 3 cycles of therapy indicates a poor prognosis. PERCENTAGE POSITIVITY OF CA 1251 {ee | Stave 2 VStage rir @ wv Increased Levels = Primary epithelial ovarian carcinoma 2 = Healthy individuals (1-2.%). ‘+ First trimester of pregnancy: ‘+ Follicular phase of menstrual cycle «Non malignant conditions - Clrhosis, Hepatitis, Endometriosis, Ovarian cysts, Pelvic Inflammatory disease + Non Ovarian malignancies - Endometrial, Pancreatic Gastrointestinal tumors. Lung, Breast, Colorectal & oltier CA 19.9 ;PANCREATIC CANCER MARKER, SERUM 20.68 imi <37.00 @ (cay Note 8 test fs not recommended to screen Pancreatic cancer in the general population